Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Drops By 16.2%

Roivant Sciences Ltd. (NASDAQ:ROIV) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 17,520,355 shares, a decline of 16.2% from the November 30th total of 20,914,523 shares. Currently, 2.8% of the shares of the company are short sold. Based on an average daily volume of 7,915,441 shares, the days-to-cover ratio is currently 2.2 days. Based on an average daily volume of 7,915,441 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.8% of the shares of the company are short sold.

Insiders Place Their Bets

In related news, Director Daniel Allen Gold sold 777,332 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $23.07, for a total transaction of $17,933,049.24. Following the transaction, the director owned 16,353,113 shares of the company’s stock, valued at $377,266,316.91. This trade represents a 4.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Vivek Ramaswamy sold 353,745 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.05, for a total value of $7,800,077.25. Following the sale, the insider directly owned 34,132,463 shares of the company’s stock, valued at approximately $752,620,809.15. This represents a 1.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 12,443,733 shares of company stock valued at $260,403,796. 10.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of ROIV. Bessemer Group Inc. increased its position in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares in the last quarter. Allworth Financial LP increased its position in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares in the last quarter. Utah Retirement Systems raised its stake in Roivant Sciences by 3.0% in the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after purchasing an additional 600 shares during the last quarter. Xponance Inc. lifted its holdings in Roivant Sciences by 1.9% in the 3rd quarter. Xponance Inc. now owns 46,718 shares of the company’s stock valued at $707,000 after purchasing an additional 882 shares in the last quarter. Finally, CWM LLC boosted its stake in shares of Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after purchasing an additional 920 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Jefferies Financial Group raised their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. The Goldman Sachs Group increased their target price on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of Roivant Sciences in a report on Thursday, December 18th. Finally, JPMorgan Chase & Co. raised their target price on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.19.

Roivant Sciences Stock Down 0.3%

Shares of ROIV stock opened at $21.63 on Wednesday. The stock has a market cap of $15.04 billion, a P/E ratio of -38.63 and a beta of 1.22. Roivant Sciences has a fifty-two week low of $8.73 and a fifty-two week high of $23.47. The business has a fifty day simple moving average of $20.73 and a 200-day simple moving average of $15.67.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.